
Addition of SBRT to Nivolumab/Ipilimumab Does Not Improve Response in mCRPC
Patients with metastatic castration-resistant prostate cancer (mCRPC) experienced a response with nivolumab (Opdivo) plus ipilimumab (Yervoy); however, the addition of stereotactic body radiation therapy (SBRT) was found to be safe but did not improve …